A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05431608
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In a study, some people will have their T cells sent to a lab to make two treatments called MCARH109 and MCARH125. Other people in the study will receive either only MCARH125 or both MCARH109 and MCARH125.
In a study, some people will have their T cells sent to a lab to make two treatments called MCARH109 and MCARH125. Other people in the study will receive either only MCARH125 or both MCARH109 and MCARH125.
Third Opinion AI Generated Synopsis
Trial Summary
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
